Isotretinoin - Unapproved indications/uses and dosage: A physician's reference

International Journal of Dermatology

Volumn 45, Issue 6, 2006, Pages 772-777

  Sehgal, Virendra N ^a,b,c,d   Srivastava, Govind ^a,b,c   Sardana, Kabir ^a,b,c  

^a Sehgal Nursing Home   (India)

^b Behl Skin Institute   (India)

^c MAULANA AZAD MEDICAL COLLEGE   (India)

^d NONE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; CORTICOSTEROID; CYCLOSPORIN; ISOTRETINOIN; METHOTREXATE; RETINOID; RETINOL;

ACANTHOSIS NIGRICANS; ANTINEOPLASTIC ACTIVITY; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CELLULITIS; CONGENITAL ICHTHYOSIFORM ERYTHRODERMA; CUTANEOUS PARAMETERS; DARIER DISEASE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG LABELING; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG UTILIZATION; EPIDERMODYSPLASIA VERRUCIFORMIS; EPIDERMOLYSIS BULLOSA; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERLIPIDEMIA; INCIDENCE; KERATOSIS PALMOPLANTARIS; LUPUS ERYTHEMATOSUS; MAINTENANCE DRUG DOSE; MEDICAL PRACTICE; NOTE; PHOTOTHERAPY; PITYRIASIS RUBRA PILARIS; PRACTICE GUIDELINE; PSORIASIS; REJUVENATION; ROSACEA; SCLEROMYXEDEMA; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; STRUCTURE ANALYSIS; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; XERODERMA PIGMENTOSUM;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ICHTHYOSIS; ISOTRETINOIN; KERATODERMA, PALMOPLANTAR; KERATOSIS FOLLICULARIS; PITYRIASIS; SKIN NEOPLASMS;

EID: 33745953790     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2006.02830.x     Document Type: Note

References (95)

1. Goldsmith LA, Bolognia JL, Chen SC, et al. American Academy of Dermatology consensus conference on the safe and optimal use of isotretinoin: Summary and recommendations. J Am Acad Dermatol 2004; 50: 900-906.
2. Ruiz-Maldonado R, Tamaya-Sanchez L, Orozco-Covarrubias MLL. The use of retinoids in the pediatric patients. Dermatol Clinic 1998; 16: 553-569.
3. Alcalay J. Myth of isotretinoin therapy in patients with acne. Drugs Dermatol 2004; 3: 179-182.
4. Hofer T. Continuous microdose isotretinoin in adult recalcitrant rosacea. Clin Exp Dermatol 2004; 29: 204-205.
5. Georgala S, Katoulis AC, Georgala C, et al. Oral isotretinoin in the treatment of recalcitrant condylomata acuminata of the cervix: A randomised placebo controlled trial. Sex Transm Infect 2004; 80: 216-218.
6. Mancuso A, Cohen EH. Transient acantholytic dermatosis treated with Isotretinoin. Int J Dermatol 1989; 28: 58-59.
7. Maddin S, Lauharanta J, Agache P, et al. Isotretinoin improves the appearance of photodamaged skin-result of a 36 weeks, multi centre double-blind placebo-controlled trial. J Am Acad Dermatol 2000; 42: 56-63.
8. Hernandez-perezt Khivaja HA, Alvarez TY. Oral Isotretinoin as a part of cutaneous aging. Dermatol Drug 2000; 26: 649-652.
9. Young HS, Coulson IH. Granuloma annulare following waxing induced pseudo folliculitis - resolution with Isotretinoin. Clin Exp Dermatol 2000; 25: 274-276.
10. Calka O, Metin A, Ozen S. A case of disseminated and recurrent infundibulo folliculitis responsive to treatment with systemic Isotretinoin. J Dermatol 2002; 29: 431-434.
11. Norris PG, Hawk JL. Actinic folliculitis - response to Isotretinoin. Clin Exp Dermatol 1989; 14: 69-71.
12. Milan CP, Cohen LE, Fenske NA, et al. Scleromyxoedema - therapeutic response to Isotretinoin in 3 patients. J Am Acad Dermatol 1988; 19: 469-477.
13. Ward A, Brogden RN, Heel RC, et al. Isotretinoin - a review of its pharmacologic properties and therapeutic efficacy in acne and other skin disorders. Drugs 1984; 28: 6-37.
14. Brazzel RK, Colburn WA. Pharmacokinatics of retinoids Isotretinoin and etretinate. J Am Acad Dermatol 1982; 6: 643-651.
15. Borok M, Lowe NJ. Pityriasis rubra pilaris-further observations on systemic retinoids therapy. J Am Acad Dermatol 1990; 22: 792-798.
16. Cohen PR, Prysttowisky JH. PRP - a review of diagnosis and treatment. J Am Acad Dermatol 1989; 20: 801-805.
17. Dickens CH. Isotretinoin treatment of PRP. J Am Acad Dermatol 1987; 16: 297-301.
18. Goldsmith LA, Weenrich AE, Shupack JL. PRP-response to 13-cis retinoic acid (Isotretinoin). J Am Acad Dermatol 1982; 6: 710-715.
19. Orfanos CE, Ehlert R, Gollnick H. the retinoids - a review of their clinical pharmacology and therapeutic uses. Drugs 1987; 34: 459-469.
20. Ruiz-Maldonado R, Tamayo L. Retinoids in disorders of keratinization - Their uses in children. Dermatologica I175 (Suppl.); 125: 1987-1991.
21. Williams ML, Shwayder TA. Ichthyosis and disorders of cornification. In: Schachner LA, Hanson RC, eds. Pediatr Dermatol, 2nd edn, Vol. 1. New York: Churchill Livingstone, 1995: 452-459.
22. Orfanos CE, Kurba M, Strank U. Oral treatment of keratosis follicularis with a new aromatic retinoid. Arch Dermatol 1978; 114: 211-214.
23. Peck GL, Yoder FW. Treatment of lamellar ichthyosis and other keratinizing disorders with an oral synthetic retinoids. Lancet 1976; 2: 1172-1173.
24. Ruiz Maldoma R, Tamajo L. Retinoids for keratinizing disease and acne in children. Dermatol Clin 1983; 1: 433-438.
25. Dickens CH, Rochester MN. Retinoids - a review. J Am Acad Dermatol 1984; 11: 541-547.
26. Fernandez-Vozmediane JM, eds. Retinoids Editions. Basel: Wizerland Roche, 1990: 59-69.
27. Tamayo L, Ruiz-Maldomado R. Long term follow up of 30 children with lamellar ichthyosis under and retinoids Ro-10-9359. In: Orfanos CE, Braun-Falco O, Farber EM, et al., eds. Retinoids Advance in Basic Research and Therapy. Berlin: Springer-Verlag, 1981: 287-289.
28. Eldauroti MA, Raubaie SM, Eiada MA. Papill-on-Lefevre syndrome successful treatment with oral retinoids in 3 patients. Int J Dermatol 1988; 27: 63-66.
29. Noguera X, Morages JM. Queratosis palmo-planter tratada con etretinats. Gacetra Dermatologica 1984; 5: 133-135.
30. Warren EW, Kanderia U. The use of retinoids in the treatment of psoriasis. Clin Pharmacy 1989; 8: 344-346.
31. Gollmicj HPM. Oral retinoids - efficacy and toxicity in psoriasis. Br J Dermatol 1996; 135: 6-9.
32. Shelnitz LSE, Sterly NB, Honig PJ. Etretinote therapy for generalized pustular psoriasis in children. Arch Dermatol 1987; 123: 230-234.
33. Kraemer KH, Digloranne JJ, Peck GL. Isotretinoin does prevent skin Cancer. Arch Dermatol 1993; 129: 43.
34. Lipmann SM, Batsakis JG, Toth BB, et al. Comparison of low dose Isotretinoin with beta carotene to present oral carcinogenesis. N Engl J Med 1993; 328: 15-20.
35. Graefe T, Wolino U, Schulz H, et al. Muir-Torre syndrome-treatment with Isotretinoin and interferon alpha-2a can prevent tumor development. Dermatology 2000; 200: 331-333.
36. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of Isotretinoin to prevent second primary tumour in stage I non-small-cell lung cancer. J Natl Cancer Institut 2001; 93: 605-618.
37. Koon saeng S, Verschraegen C, Feedman R, et al. Successful treatment of vulvar intraepithelial neoplasia resistant to interferon and Isotretinoin with cidofovir. J Med Virol 2001; 64: 195-198.
38. Boerner AR, Petrich T, Weckessser E, et al. Monitoring Isotretinoin therapy in thyroid cancer using 18f-FDG PET. Eur J Nucl Med Mol Imaging 2002; 29: 231-236.
39. Robinson WR, Anderson J, Darragh TM, et al. Isotretinoin for low grade cervical dysplasia in human immuno deficiency virus infested women. Obstet Gymaeol 2002; 99: 777-784.
40. Devic M, Apisarnthanarex N, Cohen DS, et al. Analysis of long term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2003; 49: 35-49.
41. Tsimberidou AM, Giles F, Romaguera J, et al. Activity of interferon alpha and isotretinoin in patients with advanced refractory lymphoid malignancies. Cancer 2004; 100: 574-580.
42. Pack GL. Retinoids and cancer. J Invest Dermatol 1985; 85: 87-91.
43. Kraemer KH, Di Giovamma JJ, Peck GL. Chemoprevention of skin cancer in xeroderma pymentosum. J Dermtol 1992; 19: 715-717.
44. Moshell AN. Prevention of skin cancer in xeroderma pigmetosum with oral Isotretinoin. Cutis 1989; 43: 485-487.
45. Schmitzler I. Retinoides et prevention dos epitheliomas cutaines. Ann Dermatol Venereol 1987; 114: 1537-1539.
46. Chapel KL, Rasmussen JE. Pediator dermatology - advances in therapy. J Am Acad Dermatol 1997; 36: 513-515.
47. Fine JD, Johnson LB, Weenier N, et al. Chemo prevention of squamous cell carcinoma in recessive epidermolysis bullosa-results of a phase-1 trial of systemic Isotretinoin. J Am Acad Dermatol 2004; 50: 563-571.
48. Hang WK, Leppman SM, Itri LM, et al. Prevention of second primary tumours with Isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795-801.
49. Brigges RJ, Forastiere AA. Isotretinoin for the prevention of second primary squamous cell carcinoma of the head and neck. Otolayngol Head Neck Surg 1991; 105: 752-754.
50. Goldberg LH, Hsu SHA, lcalay J. Effectiveness of Isotretinoin in preventing the appearance of basal cell carcinoma in basal cell nevus syndrome. J Am Acad Dermatol 1989; 21: 144-145.
51. Tangrea J, Edwards B, Hartiman A, et al. Isotretinoin-basal cell carcinoma prevention trial. Central Clin Trials 1990; 11: 433-450.
52. Tangrea JA, Edwards BK, Taylor PR, et al. Long term therapy with low dose Isotretinoin for prevention of basal cell carcinoma. J Natl Canncer Invst 1992; 84: 328-332.
53. Robinson JK, Salasche S. Isotretinoin dos not prevent basal cell carcinoma. Arch Dermatol 1992; 128: 975-976.
54. Armstrong RB, Lesiewicz J, Harvey G, et al. Clinical panel assessment of photo-damaged skin treated with Isotretinoin. Arch Dermatol 1992; 128: 352-356.
55. Sendagorta E, Leseiwicz J, Armstrong RB. Topical Isotretinoin for photodamaged skin. J Am Acad Dermatol 1992; 27: 515-518.
56. Kockaert M, Neurmann M. Systemic and topical drugs for aging skin. J Drugs Dermatol 2003; 2: 435-441.
57. Furner BB. Subacute cutaneous lupus erythematous response to Isotretinoin. Int J Dermtol 1990; 29: 587-590.
58. Shornick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematous. J Am Acad Dermatol 1991; 24: 49-52.
59. Richardson RT, Cohen PR. Sub acute cutaneous lupus erythematous: Report of a patients who subsequently developed melanoma and whose lesions were treated with Isotretinoin. Cutis 2000; 66: 183-188.
60. Maurice PD, Bunker CB, Dowd PM. Isotretinoin in the treatment of systemic sclerosis. Br J Dermatol 1989; 121: 367-374.
61. Bunker CB, Maurice PD, Little S, et al. Isotretinoin and lung function in systemic sclerosis. Clin Exp Dermatol 1991; 16: 11-13.
62. Berbis P, Jancovicia E, Lebrewil G, et al. Eosinophilic pustular folliculitis (ofuji's Disease) efficacy of Isotretinoin. Dermatologica 1989; 179: 214-216.
63. Koca R, Altiniyazar HC, Ozen OT, et al. Dissecting cellulitis in a white male - response to Isotretinoin. Int J Dermatol 2002; 41: 509-513.
64. Bachynsky T, Antony-shyn OM, Ross JB. Dissecting folliculitis of scalp - a case report of combined treatment using tissue expansion, radical excision and Isotretinoin. J Dermatol Surg Oncol 1992; 18: 877-880.
65. Bjellerup M, Wallengren J. Familial perifolliculitis capitis absedens et al sufffodiens in two brothers successfully treated with Isotretinoin. J Am Acad Dermatol 1990; 23: 752-753.
66. Karpouzis A, Glatroman-olaki A, Silveridis E, et al. Perifolliculitis capitis abscedens et suffodiens successfully treated with topical Isotretinoin. Eur J Dermatol 2003; 13: 192-195.
67. Goldberg LH, Rosen T, Becker J, et al. Treatment of solitary kerato-acanthoms with oral Isotretinoin. J Am Acad Dermatol 1990; 23: 934-937.
68. Monk BE. Fordyce spots responding to Isotretinoin therapy. Br J Dermatol 1993; 129: 355.
69. Saleh HH, Lloyd KM, Fatteh S. Kyrles disease: Effectively treated with Isotretinoin. J Fla Med Assoc 1993; 80: 395-397.
70. Layton AM, Cunliffe WJ. A case of ulerythema Ophryogenes responding to Isotretinoin. Br J Dermatol 1993; 129: 645-646.
71. Hodge JA, Ray MC. Cenfluent and Reticulated papillomatosis - response to Isotretinoin. J Am Acad Dermatol 1991; 24: 654.
72. Harrington KJ, Price FM, Fry L, et al. Erythroplasia of Queyrat treatment with Isotretinoin. Lancet 1993; 342: 994-995.
73. Hisler BM, Savoy LB, Hashimoto K. Improvement of scleromyxoedema associated therapy. J AM Acad Dermatol 1991; 24: 854-857.
74. Edwards L, Meyskens F, Levine N. Effect of Isotretinoin on dysplastic nevi. J Am Acad Dermatol 1989; 20: 257-260.
75. Herman AR, Scott RA. Systematized epidermal nerves treated with Isotretinoin. J Drugs Dermatol 2002; 1: 195-196.
76. Schlevicher SM, Milsteen HJ, Lim SJ, et al. Resolution of disseminated granuloma annulare with Isotretinoin. Int J Dermatol 1992; 31: 371-372.
77. Adams DC, Hogan DJ. Improvement of chronic generalized granuloma annulare with Isotretinoin. Arch Dermatol 2002; 138: 1518-1519.
78. Buendia-Eisman A. Generalized annular granuloma - response to Isotretinoin. Int J Dermatol 2003; 42: 321-322.
79. Looney M, Smith KM. Isotretinoin in the treatment of granuloma annulare. Ann Pharmacother 2004; 38: 494-497.
80. Firooz A, Firoozabadi MR, Dowlati Y. Rosacea fulmicinas (pyoderma faciale): Successful treatment of a 3-year old girl with oral Isotretinoin. Int J Dermatol 2001; 40: 203-205.
81. Smith KW. Perioral dermatitis with histopathologic features of granulomaotus rosacea - successful treatment with Isotretinoin. Cutis 1990; 46: 413-415.
82. Apaydin R, Bilen N, Bayramgurler D, et al. Steatocystoma multiplex supperativum-oral Isotretinoin treatment combined with cryo therapy. Austrian J Dermatol 2000; 41: 98-100.
83. Moritz DL, Silverman RA. Steatocystoma multiplex treated with Isotretinoin - a delayed response. Cutis 1988; 42: 437-439.
84. Oslen EA, Kelly FF, Vollmer RT, et al. Comparative study of systemic interferon alfa-1 and Isotretinoin in treatment of resistant condylomata acuminate. J Am Acad Dermatol 1989; 20: 1023-1030.
85. Mamcuso A, Cohen EH. Transient acantholytic dermatois treated with Isotretinoin. J Am Osteopath Assoc 1990; 90: 179-182.
86. Akyol M, Dogan S, Kaptanoglin E, et al. Systemic Isotretinoin in the treatment of a Belicatis patients with arithmetic symptoms and acne lesions. Clin Exp Rheumatol 2002; 20: S-55.
87. McLaughlin ER, Morris R, Weiss SW, et al. Diffuse dermal angiomatosis of the breast - response to Isotretinoin. J Am Acad Dermatol 2001; 45: 462-465.
88. Chang Ly Kuo TT, Chan HL. Extranodal Rosai-Dorfman disease with cutaneous ophthalmic, and larynged involvement-report of a case treated with Isotretinoin. Int J Dermatol 2002; 41: 888-891.
89. Ampel NM, Stout ML, Garewal HS, et al. Persistent rectal ulcer associated with HPV-33 ina patient with AIDS - successful treatment with Isotretinoin. Rev Infect Dis 1990; 12: 1004-1007.
90. Mahr G. Isotretinoin and trichotillomania. Psychosomatic I 1990; 31: 235.
91. Park YK, Kemi HJ, Chung Ky. Pachydermoperiostosis - trial with Isotretinoin. Yonsei Med 1988; 29: 204-207.
92. Jamshidi M, Pbermeyer RJ, Gormidrag XX, et al. Acute pancreatitis secondary to Isotretinoin-induced hyperlipidemia. J Okla State Med Assoc 2002; 95: 79-80.
93. Gruss C, Zillikens D, Hashimoto T, et al. Rapid response of IgA-pemphigus of sub-corneal pustular dermatosis type to treatment with Isotretinoin. J Am Acad Dermatol 2000; 43: 923-926.
94. Walling HW, Messing Larm M, Myers LM, et al. Improvement of acanthosis nigricans on Isotretinoin and metformin. J Drugs Dermatol 2003; 2: 677-681.
95. Sardana K, Sehgal VN. Retinoids: Fascinating up-and-coming scenario. J Dermatol (Tokyo) 2003; 30: 355-380.